ITC as a Biosimilar Battleground: Genentech Challenges Biocon’s Pertuzumab Biosimilar

On February 27, 2026, Genentech filed a complaint at the U.S. International Trade Commission (ITC) alleging that Biocon’s importation of its pertuzumab biosimilar, BMAB 1500/PERT-IJS (“BMAB 1500”), violates 19 U.S.C. § 1337 (“Section 337”). Biocon’s Biologics License Application (“BLA”) for BMAB 1500 references Genentech’s PERJETA (pertuzumab), a HER2-directed monoclonal antibody therapy used in treatment of HER2-positive breast cancer...... By: Rothwell, Figg, Ernst & Manbeck, P.C.